• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

东京国家癌症中心医院(NCCH)生物库中临床后测试样本的去识别程序和样本质量。

De-identification procedure and sample quality of the post-clinical test samples at the bio-repository of the National Cancer Center Hospital (NCCH) in Tokyo.

机构信息

Division of Clinical Laboratories, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

出版信息

Jpn J Clin Oncol. 2011 Feb;41(2):295-8. doi: 10.1093/jjco/hyq172. Epub 2010 Sep 18.

DOI:10.1093/jjco/hyq172
PMID:20852301
Abstract

We established our bio-repository in October 2002. One of the unique aspects of our bio-repository is that it is based on post-clinical test samples. Although the post-clinical test sample-based storage is beneficial because ample clinical information is available for each sample and samples are to be refreshed regularly, many bio-bankers are hesitant to store them because of the possible problems of de-identification procedures and sample quality. Currently, we have two different types of sample, not de-identified status and de-identified status. Most of the samples for storage are not de-identified status. A portion of the samples are transferred to new tubes before and after being frozen, without clinical patient identifications and the status is de-identified. This tube transfer is the only de-identification procedure in our bio-repository so far. After a procedure of de-identification, these samples are stored. The de-identified samples are collected under various project-based schemes. The quality standards of our samples are established by two factors: pre-analytical quality control efforts, and record keeping of sample history by sample tracking system. All the samples have been phlebotomized under strict control of pre-analytical requirements. By record keeping of sample history with the sample tracking system, we can tell the exact temperature and elapsed time in various situations since the phlebotomy procedure or on arrival at the clinical laboratory. In this article, we will disclose how we have dealt with the de-identification procedure and sample quality.

摘要

我们于 2002 年 10 月建立了我们的生物库。我们的生物库的一个独特之处是它基于临床测试后的样本。虽然基于临床测试后的样本储存是有益的,因为每个样本都有充足的临床信息,并且样本将定期更新,但许多生物库管理员因为可能存在的去识别程序和样本质量问题而犹豫不决。目前,我们有两种不同类型的样本,一种是未去识别状态,另一种是已去识别状态。大多数用于储存的样本都未去识别。一部分样本在冷冻前后被转移到新的管子中,没有临床患者的识别信息,状态是去识别的。这是我们生物库迄今为止唯一的去识别程序。在去识别程序之后,这些样本被储存起来。已去识别的样本是根据各种基于项目的计划收集的。我们的样本质量标准由两个因素确定:分析前质量控制措施,以及通过样本跟踪系统记录样本历史。所有样本都是在严格的分析前要求控制下进行采血的。通过样本跟踪系统记录样本历史,我们可以在采血程序或到达临床实验室后的各种情况下,准确地记录温度和时间流逝。在本文中,我们将披露我们如何处理去识别程序和样本质量问题。

相似文献

1
De-identification procedure and sample quality of the post-clinical test samples at the bio-repository of the National Cancer Center Hospital (NCCH) in Tokyo.东京国家癌症中心医院(NCCH)生物库中临床后测试样本的去识别程序和样本质量。
Jpn J Clin Oncol. 2011 Feb;41(2):295-8. doi: 10.1093/jjco/hyq172. Epub 2010 Sep 18.
2
Bio-repository of post-clinical test samples at the national cancer center hospital (NCCH) in Tokyo.
Jpn J Clin Oncol. 2009 Aug;39(8):534-9. doi: 10.1093/jjco/hyp049. Epub 2009 Jun 2.
3
[Re-utilization of clinical laboratory patient-derived samples].
Rinsho Byori. 2006 Sep;54(9):918-23.
4
[Improvement of routine works and quality control in mycobacterial laboratory].[分枝杆菌实验室日常工作及质量控制的改进]
Kekkaku. 2007 Mar;82(3):217-27.
5
Nordic biological specimen bank cohorts as basis for studies of cancer causes and control: quality control tools for study cohorts with more than two million sample donors and 130,000 prospective cancers.北欧生物样本库队列作为癌症病因与控制研究的基础:针对拥有超过两百万样本捐赠者和13万例前瞻性癌症病例的研究队列的质量控制工具
Methods Mol Biol. 2011;675:61-112. doi: 10.1007/978-1-59745-423-0_3.
6
[What are the requirements for establishing a biological specimen bank?].[建立生物样本库有哪些要求?]
Ugeskr Laeger. 2003 Apr 14;165(16):1686-8.
7
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.美国临床肿瘤学会政策声明更新:癌症易感性基因检测
J Clin Oncol. 2003 Jun 15;21(12):2397-406. doi: 10.1200/JCO.2003.03.189. Epub 2003 Apr 11.
8
[2002 Standards, Options and Recommendations: good practice for the management and shipment of histological and cytopathological cancer specimens].[2002年标准、选项与建议:组织学和细胞病理学癌症标本管理与运输的良好规范]
Ann Pathol. 2003 Jun;23(3):266-78.
9
[Standards, Options and Recommendations: good practice for the management and shipment of histological and cytopathological cancer specimens].[标准、选项与建议:组织学和细胞病理学癌症标本管理与运输的良好实践]
Bull Cancer. 2002 Apr;89(4):401-9.
10
Organization of a tumor bank: the experience of the National Cancer Institute of Mexico.肿瘤库的组织:墨西哥国家癌症研究所的经验。
Pathobiology. 2010;77(3):147-54. doi: 10.1159/000292648. Epub 2010 May 28.

引用本文的文献

1
Genetic data sharing and privacy.遗传数据共享与隐私
Neuroinformatics. 2015 Jan;13(1):1-6. doi: 10.1007/s12021-014-9248-z.
2
Strategies for de-identification and anonymization of electronic health record data for use in multicenter research studies.用于多中心研究的电子健康记录数据去识别和匿名化策略。
Med Care. 2012 Jul;50 Suppl(Suppl):S82-101. doi: 10.1097/MLR.0b013e3182585355.